Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email



**NEWS ALERT** CANTOS and REVEAL studies both meet the primary study endpoint

(Canakinumab Anti-inflammatory Thrombosis Outcomes Study) showing that each study had met its primary endpoint (1,2).
On June 22, Novartis confirmed that the CANTOS study met the primary endpoint, showing that when used in combination with standard of care, canakinumab (a monoclonal antibody to interleukin 1?) reduced the primary composite endpoint of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke, in patients with a prior myocardial infarction and inflammatory atherosclerosis.
Added to this, five days later Merck announced that the REVEAL study met its primary endpoint, significantly reducing major coronary events (defined as the composite of coronary death, myocardial infarction, and coronary revascularization) with the addition of the cholesteryl ester transfer protein (CETP) inhibitor anacetrapib compared to placebo in patients at risk for cardiac events who were already on optimised low-density lipoprotein cholesterol lowering treatment. The safety profile of anacetrapib was generally consistent with that observed in recent CETP-inhibition studies. Anacetrapib is the last of the CETP inhibitors in clinical development, following the termination of evacetrapib after the failure of ACCELERATE.
We wait for the full results at the European Society of Cardiology Congress in Barcelona, Spain, this August.
1. Press release, Novartis 22 June 2017.
2. Press release, Merck, 27 June 2017.
**NEWS ALERT** CANTOS and REVEAL studies both meet the primary study endpoint